Highlighted Scientific Opportunities
NCI continually pursues new and emerging scientific opportunities that, with further investment, would catalyze additional progress in cancer research. Read about four areas of opportunity highlighted in the Fiscal Year 2023 Annual Plan and Budget Proposal.
Ending cancer as we know it means reimagining the clinical trial enterprise so that clinical research is available to participants wherever they are. With additional investments, NCI can support more research to expand telemedicine into clinical trials, increase access to trials for underserved communities, and incorporate methods that simplify enrollment and data collection.
A future with safe and effective cancer medicines that are available for every patient would end cancer as we know it. Additional investments in computational methods that rapidly screen billions of molecules for targeted interactions could speed drug discovery dramatically. This approach could produce a greater number of cancer drugs that work more effectively to save lives with fewer toxic side effects.
A precision approach to prevention could end cancer as we know it by limiting suffering and death for those at risk and helping others avoid unnecessary tests and treatments. Imagine determining a person’s cancer risk by assessing their genetic makeup, family history, environmental exposures, and behaviors and then tailoring personalized prevention approaches based on these factors. Accomplishing this goal requires a deeper understanding of the causes of cancer and cancer biology.
Ending cancer as we know it includes a future in which we can predict a tumor’s trajectory based on a detailed profile of each patient’s disease and develop personalized approaches to care. Addressing the complexity of cancer will require additional investments in basic research, coupled with resources including tumor atlases and advances in computer science and molecular techniques.